Predicting HIV viral non-suppression in Uganda: development and validation of machine learning and risk stratification models using routine EMR data
Résumé
Background: Viral non-suppression is the primary actionable risk state in routine HIV care, yet most individuals are identified after virological failure and/or drug resistance, rather than proactively. In Uganda and similar resource-limited settings, routine electronic medical records (EMR) are collected at scale but remain underused for targeted, data-enabled risk stratification. We aimed to develop and internally validate machine learning and regularized regression models for predicting viral non-suppression using routine monitoring data. Methods: = 33,384). Twenty variables were used across four models: logistic regression (LR), elastic net regularized logistic regression (ENET), random forest (RF), and extreme gradient boosting (XGB), evaluated on a stratified 80:20 test set. Precision-recall AUC (PR-AUC) was the primary metric; ROC-AUC, Brier score, and decision curve analysis were assessed; bootstrap 95% CIs (2,000 replicates) were computed for discrimination metrics. Results: = 6,677), RF achieved PR-AUC 0.248 (95% CI 0.207-0.291) and ROC-AUC 0.758 (0.732-0.780); ENET achieved PR-AUC 0.237 (0.198-0.279) and ROC-AUC 0.750 (0.726-0.772); confidence intervals overlapped across all four models. RF and ENET achieved Brier scores of 0.055 (8% below the null of 0.060) and maximum net benefit of 0.055 in decision curve analysis. At the capacity-first threshold (top 5% predicted risk), RF flagged 325 individuals (4.9%; PPV 0.338, NPV 0.949) and ENET flagged 334 (5.0%; PPV 0.305, NPV 0.948). Current ART class (PI-based: OR 11.07; NNRTI-based: OR 4.80), poor adherence (OR 7.71), TB history (OR 2.08), and male sex (OR 1.62) were the strongest predictors. Conclusions: Routine EMR data support meaningful, calibrated viral non-suppression risk prediction across a large, multi-site Ugandan HIV program. At a capacity-first threshold, both models achieved approximately five-fold enrichment over background prevalence, with clinical utility confirmed by decision curve analysis. Prospective external validation and workflow integration are required before deployment.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 02/10/2026. Le document reste hébergé par sa source.
Voir le document à la source →